Toggle Dropdown
Groups
Announcements
Projects
News & Events
Welcome guest
Log in
Friends
Loading
Loading...
https://www.prnewswire.com/news-releases/results-of-novel-clinical-study-of-guselkumab-and-golimumab-combination-therapy-show-adults-with-moderately-to-severely-active-ulcerative-colitis-maintained-higher-rates-of-clinical-histologic-and-endoscopic-remission-at-week-38-301644127.html
0
0
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38 - PR Newswire
10/10/22 at 10:30am
Organization
PRNewswire
56 words
0
Comments
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing...
Health
Novel Clinical Study of Guselkumab
Golimumab Combination Therapy Show
Histologic
Endoscopic Remission
PRNewswire
Phase 2a
Janssen Pharmaceutical Companies of Johnson & Johnson
You are the first to view
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...